This coming February 28.
Would you also like to participate?
Learn more: https://www.rarediseaseday.org/article/get-involved
This coming February 28.
Would you also like to participate?
Learn more: https://www.rarediseaseday.org/article/get-involved
Researchers from Inserm and the NeuroCentre Magendie (Bordeaux) published a fascinating study in August 2025: they successfully stimulated mitochondrial activity
Mitochondrial diseases are rare, complex, and often misdiagnosed. This is why MITOMICS, an ambitious French project funded as part of
MEET THE PEOPLE BEHIND Epilepsy Plus – E+ Introducing Emma Del Rey, E+ consultant, Board Member of International Mito Patients,
Researchers from Inserm and the NeuroCentre Magendie (Bordeaux) published a fascinating study in August 2025: they successfully stimulated mitochondrial activity
Mitochondrial diseases are rare, complex, and often misdiagnosed. This is why MITOMICS, an ambitious French project funded as part of
MEET THE PEOPLE BEHIND Epilepsy Plus – E+ Introducing Emma Del Rey, E+ consultant, Board Member of International Mito Patients,
The FDA (U.S. Food and Drug Administration) has just approved Kygevvi, the first treatment for thymidine kinase 2 deficiency (TK2d),
Many voices, one mission. 53 associations united for people with rare and complex epilepsies (E+). E+ is not limited to
MARK YOUR CALENDAR: November 15, 2025 Day dedicated to the transition to adulthood for adolescents with rare diseases: TOULOUSE This
Association for Mitochondrial Diseases
6, impasse Jacques Prévert
31470 Sainte-Foy-de-Peyrolières
Phone: +33 6 30 84 58 27
Email: assoammi@gmail.com
A.M.Mi is a co-founder and member of:
© AMMi 2025 – All rights reserved – WordPress site expertise and development by www.md-webdesigner.com